Literature DB >> 26202667

The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer.

Heidi Schwarzenbach1.   

Abstract

In cancer, deregulated expression levels of miRNAs are associated with tumorigenesis, tumor progression, metastasis and drug resistance. Apart from their release by apoptotic and necrotic cells, miRNAs can also be actively secreted into the blood circulation by exosomes. Exosomal miRNAs are thought to play an important role in cell-to-cell communication. Based on their biological functions and the possibility of quantifying miRNAs in patient blood in real time, these small non-coding RNA molecules may be a new promising class of potential non-invasive biomarkers. Screening of these liquid biopsies may provide information on target molecules of miRNAs and aberrant signaling pathways that can be blocked by a chosen targeted therapy. Consequently, therapy-associated modulations may facilitate treatment decisions. The present article discusses the potential clinical use of exosomal miRNAs as diagnostic and prognostic tumor markers. The emerging role of exosomes as a mediator of cell-to-cell signaling, to transfer miRNAs between cells, is also discussed.

Entities:  

Keywords:  cell-to-cell communication; diagnosis; exosomes; miRNAs; prognosis; signal pathways

Mesh:

Substances:

Year:  2015        PMID: 26202667     DOI: 10.1586/14737159.2015.1069183

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  36 in total

Review 1.  Extracellular vesicles in breast cancer drug resistance and their clinical application.

Authors:  Shentong Yu; Yifang Wei; Yuqiao Xu; Yuan Zhang; Jipeng Li; Jian Zhang
Journal:  Tumour Biol       Date:  2016-01-21

Review 2.  Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application.

Authors:  Zhen Zhao; Jia Fan; Yen-Michael S Hsu; Christopher J Lyon; Bo Ning; Tony Y Hu
Journal:  Lab Chip       Date:  2019-03-27       Impact factor: 6.799

3.  CD133 positive U87 glioblastoma cells-derived exosomal microRNAs in hypoxia- versus normoxia-microenviroment.

Authors:  Guobin Zhang; Yunsheng Zhang; Sen Cheng; Zhen Wu; Fusheng Liu; Junting Zhang
Journal:  J Neurooncol       Date:  2017-09-25       Impact factor: 4.130

4.  A novel assay for exosomal and cell-free miRNA isolation and quantification.

Authors:  Magdalena Grunt; Antonio Virgilio Failla; Ines Stevic; Timo Hillebrand; Heidi Schwarzenbach
Journal:  RNA Biol       Date:  2020-02-10       Impact factor: 4.652

5.  Exosomal lncRNAs as new players in cell-to-cell communication.

Authors:  Mihnea Dragomir; Baoqing Chen; George A Calin
Journal:  Transl Cancer Res       Date:  2018-03       Impact factor: 1.241

Review 6.  Potential Therapies by Stem Cell-Derived Exosomes in CNS Diseases: Focusing on the Neurogenic Niche.

Authors:  Alejandro Luarte; Luis Federico Bátiz; Ursula Wyneken; Carlos Lafourcade
Journal:  Stem Cells Int       Date:  2016-04-19       Impact factor: 5.443

7.  Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.

Authors:  Xiaodan Meng; Volkmar Müller; Karin Milde-Langosch; Fabian Trillsch; Klaus Pantel; Heidi Schwarzenbach
Journal:  Oncotarget       Date:  2016-03-29

Review 8.  Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation.

Authors:  Dora Brites; Adelaide Fernandes
Journal:  Front Cell Neurosci       Date:  2015-12-17       Impact factor: 5.505

Review 9.  miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition.

Authors:  Siti A Sulaiman; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2016-08-23       Impact factor: 5.810

Review 10.  The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.

Authors:  Jiulue Hu; Jelena Stojanović; Saman Yasamineh; Pooneh Yasamineh; Sathish Kumar Karuppannan; Mohammed Junaid Hussain Dowlath; Hamed Serati-Nouri
Journal:  Arch Virol       Date:  2021-07-19       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.